ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer

ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer

Abstract Mutated KRAS serves as the oncogenic driver in 30% of non-small cell lung cancers (NSCLCs) and is associated with metastatic and therapy-resistant tumors. Focal Adhesion Kinase (FAK) acts as a mediator in sustaining KRAS-driven lung tumors, and although FAK inhibitors are currently undergoi...

Full description

Saved in:
Bibliographic Details
Main Authors: Chiara Pozzato, Gonçalo Outeiro-Pinho, Mirco Galiè, Giorgio Ramadori, Georgia Konstantinidou
Format: Article
Language:English
Published: Springer Nature 2024-09-01
Series:EMBO Molecular Medicine
Subjects:
Lung Cancer
Focal Adhesions
Drug Resistance
Combination Therapy
FAK and ERK5 Inhibitors
Online Access:https://doi.org/10.1038/s44321-024-00138-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s44321-024-00138-7

Similar Items